Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | APOL1 | O14791 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6385322 | 1.00 | HPGDS (0.41) | HPGDSMAPK1SCN9ANAMPTAPOL1 | |
| SCHEMBL2464736 | 0.89 | NAMPT (0.43) | HPGDSMAPK1NAMPTMMEACE | |
| SCHEMBL5639144 | 0.87 | NAMPT (0.47) | NAMPTMMEACENAAA | |
| SCHEMBL15998895 | 0.85 | HPGDS (0.41) | HPGDSMAPK1SCN9ANAMPTAPOL1 | |
| SCHEMBL23022786 | 0.83 | HPGDS (0.41) | HPGDSMAPK1SCN9ANAMPTAPOL1 | |
| SCHEMBL30107181 | 0.83 | HPGDS (0.41) | HPGDSMAPK1SCN9ANAMPTAPOL1 | |
| SCHEMBL21246180 | 0.83 | HPGDS (0.41) | HPGDSMAPK1SCN9ANAMPTAPOL1 | |
| SCHEMBL27749158 | 0.83 | HPGDS (0.36) | HPGDSMAPK1SCN9ANAMPTAPOL1 | |
| SCHEMBL27283601 | 0.80 | CYP1A2 (0.40) | HPGDSSCN9ANAMPTMMEACE | |
| SCHEMBL10713076 | 0.79 | NAMPT (0.55) | HPGDSNAMPTDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090149443-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149443-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPK1, MAPK4, BRIX1 | HPGDS 2025/4885MAPK1 1/4885SCN9A 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.